Short Interest in HeartSciences Inc. (NASDAQ:HSCS) Declines By 18.2%

HeartSciences Inc. (NASDAQ:HSCS) saw a large decrease in short interest in April. As of April 15th, there was short interest totaling 28,778 shares, a decrease of 18.2% from the March 31st total of 35,192 shares. Based on an average daily volume of 14,161 shares, the short-interest ratio is presently 2.0 days. Approximately 1.0% of the company’s shares are sold short.

Analyst Ratings Changes

Several research analysts have issued reports on HSCS shares. Weiss Ratings reiterated a “sell (e+)” rating on shares of HeartSciences in a report on Friday, March 27th. Ascendiant Capital Markets cut their price target on HeartSciences from $9.00 to $8.00 and set a “buy” rating on the stock in a report on Tuesday, March 24th. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $8.00.

HeartSciences Stock Up 2.1%

NASDAQ:HSCS traded up $0.04 on Friday, hitting $1.99. The stock had a trading volume of 5,915 shares, compared to its average volume of 25,872. The business’s fifty day moving average is $2.38 and its 200 day moving average is $2.77. The company has a market cap of $6.33 million, a PE ratio of -0.40 and a beta of 2.03. The company has a quick ratio of 1.04, a current ratio of 1.19 and a debt-to-equity ratio of 0.16. HeartSciences has a 52 week low of $1.89 and a 52 week high of $6.47.

HeartSciences (NASDAQ:HSCS) last announced its quarterly earnings results on Thursday, March 12th. The company reported ($0.63) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.84) by $0.21. On average, equities research analysts expect that HeartSciences will post -3.28 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of HSCS. Geode Capital Management LLC bought a new position in shares of HeartSciences in the second quarter valued at approximately $43,000. TFB Advisors LLC bought a new position in shares of HeartSciences in the third quarter valued at approximately $105,000. Finally, DRW Securities LLC lifted its holdings in shares of HeartSciences by 13.7% in the fourth quarter. DRW Securities LLC now owns 95,065 shares of the company’s stock valued at $294,000 after purchasing an additional 11,455 shares in the last quarter. Institutional investors own 17.24% of the company’s stock.

HeartSciences Company Profile

HeartSciences, Inc (NASDAQ: HSCS) is a medical device company focused on the development and commercialization of advanced, non‐invasive cardiac diagnostic technologies. The company’s flagship product, MyoVista, is a high‐fidelity electrocardiograph (ECG) designed to detect subtle changes in cardiac function that may indicate myocardial ischemia or left ventricular dysfunction. By leveraging high‐frequency wavelet analysis within the QRS complex, MyoVista provides clinicians with enhanced visualization and analytical capabilities that extend beyond those of standard ECG systems.

HeartSciences supports the MyoVista system with an integrated software suite that automates data analysis and report generation, facilitating seamless integration into existing clinical workflows.